A highly diverse team imagining the undiscovered

RENAL RESEARCH INSTITUTE

Transforming
patient care
through data-driven
innovation

ABOUT THE RENAL RESEARCH INSTITUTE

The heart of RRI’s capacity for innovation is our ability to examine complex problems through multiple lenses.

The Renal Research Institute (RRI) is an internationally recognized incubator of ideas, treatment processes, and technologies to improve the lives of kidney patients. RRI’s leadership in data analytics, computational biomedicine and AI, as well as our access to a large patient population, accelerates the pace of scientific discoveries and their translation into applied medicine. Our team includes some of the brightest minds from around the world, who, along with their disciplinary expertise, bring a deep understanding of global healthcare issues and challenges.

 

Our Research

We operate at the intersection of clinical data, machine data, and real-world practice, with access to a large patient population and one of the world's largest and richest renal datasets. Our deep connection to the scientific community and to med-tech innovators gives us the rare ability to translate insight into action—quickly, precisely, and meaningfully.

 

Latest Research & News

Latest Research

  • Yan Zhang, Anke Winter, Linda H Ficociello, Belén Alejos Ferreras, Paola Carioni, Christian Apel, Otto Arkossy, Michael Anger, Robert Kossmann, Len A Usvyat, Stefano Stuard

    RESULTSA total of 71,669 patients were included, with 45% receiving HD and 55% receiving HDF. During the follow-up period, patients in the HDF group underwent a total of 12,741,453 HDF treatments, with a mean convection volume of 25.8L. Compared to HD, treatment with HDF was associated with a lower incidence of both hospital admissions (adjusted IRR, 0.80; 95% confidence interval [CI], 0.79-0.82) and days spent in the hospital (adjusted IRR, 0.80; 95% CI, 0.78-0.82). These reductions were consistent across subgroups analyzed and across most major causes of hospitalization, including cardiovascular disease, infections, and fluid-related complications.CONCLUSIONSIn this large, real-world cohort spanning multiple regions and dialysis centers, HV-HDF was associated with significantly lower rates of both hospital admissions and days spent in the hospital compared to treatment with high-flux HD. These findings suggest that HV-HDF may have the potential to reduce morbidity in patients with ESKD.BACKGROUNDPatients with end stage kidney disease undergoing hemodialysis (HD) experience high rates of hospitalizations and mortality, partly due to the incomplete removal of some toxic uremic molecules. To improve outcomes, multiple modalities of kidney replacement therapy have been developed, including high-flux HD and on-line hemodiafiltration (HDF). Notably, on-line high-volume HDF (HV-HDF) has demonstrated mortality benefits over high-flux HD in some randomized trials.METHODSThis retrospective cohort study evaluated hospitalization outcomes among in-center dialysis patients treated with HV-HDF and high-flux HD at Fresenius Medical Care NephroCare centers across Europe, the Middle East, and Africa between January 2019 and December 2022. Data were extracted from the European Clinical Database. The primary outcome was all-cause hospitalization; secondary outcomes included cause-specific hospitalizations. Negative binomial regression was used to estimate incidence rate ratio (IRR) for hospital outcomes, incorporating inverse probability of treatment weighting (IPTW) to adjust for baseline differences between treatment groups.

No Results Found

Latest News

No Results Found

Education

LATEST EPISODE

Beyond Medicine: Coaching, Movement & Mindset in Chronic Disease

December 1, 2025

In this episode of Frontiers in Kidney Medicine and BioIntelligence, Len Usvyat, Head of Clinical Advanced Analytics at the Renal Research Institute, speaks with Ingrid Adelsberger, a National Board-Certified Health and Wellness Coach who has lived with multiple sclerosis for more than 15 years. 

Together, they explore the intersection of health coaching, exercise, and nutrition—and how these approaches can empower people with chronic conditions, including those with chronic kidney disease, to take active roles in their health. 

Topics discussed: 
• What health coaching really is—and how it differs from therapy or social work 
• How small lifestyle changes lead to lasting improvements 
• Nutrition and cultural context in kidney care 
• Group coaching and the role of community support 
• Technology, wearables, and AI in behavior change